RXRX · XBRL financial data

Recursion Pharmaceuticals financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (RXRX's year ends in late December)

In millions of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Revenue from contracts with customers	11*	14	14	26	5*	15	19	5	36*	6	8	19
Cost of goods and services sold	10*	11	9	12	13*	22	20	15	14*	12	11	10
Research and development	69*	68	74	75	98*	130	129	121	96*	88	90	99
General and administrative	30*	31	32	38	77*	55	47	42	34*	35	42	33
Operating income (loss)	(99)*	(96)	(101)	(98)	(184)*	(191)	(176)	(172)	(108)*	(129)	(135)	(123)
Interest expense	0*	0	0	1	1*	1	0	1	(0)*	0	0	0
Income tax expense (benefit)	(4)*	(1)	(1)	0	0*	(0)	0	0	0*	(5)	(0)	0
Net income (loss)	(93)*	(91)	(98)	(96)	(179)*	(202)	(172)	(162)	(108)*	(118)	(131)	(119)
Earnings per share, basic USD per share	(0.42)*	(0.39)	(0.40)	(0.34)	(0.53)*	(0.50)	(0.41)	(0.36)	(0.21)*	(0.22)	(0.25)	(0.22)
Earnings per share, diluted USD per share	(0.42)*	(0.39)	(0.40)	(0.34)	(0.53)*	(0.50)	(0.41)	(0.36)	(0.21)*	(0.22)	(0.25)	(0.22)
Weighted average shares, basic millions of shares	224*	236	242	283	335*	403	417	447	521*	529	532	543
Weighted average shares, diluted millions of shares	224*	236	242	283	335*	403	417	447	521*	529	532	543

Fiscal quarters (RXRX's year ends in late December)

In millions of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Cash and cash equivalents	392	296	474	428	594	500	525	660	743	654	546	550
Total current assets	438	344	522	474	714	584	587	714	813	710	603	616
Property and equipment, net	87	87	84	84	141	127	120	112	104	96	90	86
Right-of-use asset	34	36	44	48	66	53	50	48	45	43	40	51
Goodwill	52	52	52	52	149	158	164	162	162	160	160	161
Total assets	654	558	776	726	1,449	1,305	1,302	1,400	1,474	1,340	1,213	1,222
Accounts payable	4	5	4	2	22	25	19	14	18	20	13	16
Accrued liabilities	47	26	33	41	82	57	64	53	70	54	57	67
Total current liabilities	93	74	86	109	187	142	164	155	148	130	120	123
Lease liability, non-current	43	44	50	54	67	56	53	50	47	43	39	51
Total liabilities	190	157	191	202	414	371	383	353	343	315	298	316
Accumulated deficit	(968)	(1,059)	(1,157)	(1,252)	(1,431)	(1,634)	(1,806)	(1,968)	(2,076)	(2,194)	(2,325)	(2,444)
Total stockholders' equity	463	401	584	525	1,035	934	919	1,047	1,131	1,025	915	906
Total liabilities and equity	654	558	776	726	1,449	1,305	1,302	1,400	1,474	1,340	1,213	1,222
Common shares outstanding (cover page) millions of shares	234	238	281	286	397	406	433	492	528	531	535	623

Fiscal quarters (RXRX's year ends in late December)

In millions of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Net income (loss)	(93)*	(91)	(98)	(96)	(179)*	(202)	(172)	(162)	(108)*	(118)	(131)	(119)
Stock-based compensation	16*	16	17*	18*	31*	36	26*	25*	24*	22	19*	23*
Depreciation and amortization	8*	7	9*	7*	13*	19	24*	21*	19*	20	18*	17*
Net cash from operating activities	(74)*	(102)	(82)*	(59)*	(115)*	(132)	(76)*	(117)*	(46)*	(81)	(106)*	(77)*
Purchases of property and equipment	2*	7	1*	5*	1*	2	3*	0*	1*	0	0*	0*
Net cash from investing activities	(2)*	(7)	(4)*	(5)*	275*	(7)	(6)*	(3)*	(1)*	(0)	(2)*	(0)*
Proceeds from issuing common stock	78*	11	262*	17*	11*	41	100*	254*	133*	0	0*	86*
Repayments of long-term debt	1*	0	0*	—	—	—	—	—	—	—	—	—
Net cash from financing activities	81*	14	263*	16*	11*	41	98*	251*	132*	(3)	(1)*	83*
Net change in cash	4*	(95)	177*	(47)*	167*	(94)	25*	133*	87*	(89)	(108)*	5*

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Recursion Pharmaceuticals	550	19	(77)*	622.8M	6.2 quarters	Q3 FY26 10-QSep 30, 2026
Bausch Health Companies	2,485	2,941	814*	374.3M	—	Q3 FY26 10-QSep 30, 2026
Vericel	125	77	16*	51.2M	—	Q2 FY26 10-QJun 30, 2026
Agios Pharmaceuticals	100	45	(57)*	59.7M	10.8 quarters	Q2 FY26 10-QJun 30, 2026
Biocryst Pharmaceuticals	155	not reported	104*	255.5M	—	Q2 FY26 10-QJun 30, 2026
Indivior Pharmaceuticals	305	356	97*	118.0M	—	Q3 FY26 10-QSep 30, 2026
Apellis Pharmaceuticals	405	268	(61)	128.0M	6.6 quarters	Q1 FY26 10-QMar 31, 2026
Acadia Pharmaceuticals	385	308	101*	172.3M	—	Q2 FY26 10-QJun 30, 2026
Twist Bioscience	117	not reported	1.1*	62.7M	—	Q3 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.